PET/CT Predicts Response to Drug Combo in HER2-Positive Breast Cancer

PET/CT Predicts Response to Drug Combo in HER2-Positive Breast Cancer
The combination of lapatinib plus trastuzumab for patients with metastatic HER2-positive breast cancer resulted in high response rates when used early. Additionally, undergoing [18F]fluorodeoxyglucose positron emission tomography/computed tomography …
Read more on Cancer Network

Immunotherapy for Genitourinary Cancers Still in Infancy
As part of our coverage of the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting held May 29 to June 2 in Chicago, today we are speaking with Susan F. Slovin, MD, PhD, attending physician, member of genitourinary oncology services at …
Read more on Cancer Network

This entry was posted in Searchmedica and tagged , , , , , , , . Bookmark the permalink.